Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-17-140858
Filing Date
2017-04-27
Accepted
2017-04-27 07:05:02
Documents
6
Effectiveness Date
2017-04-27

Document Format Files

Seq Description Document Type Size
1 DEFA14A d379513ddefa14a.htm DEFA14A 38989
2 GRAPHIC g379513g93i65.jpg GRAPHIC 1832
3 GRAPHIC g379513gr0001.jpg GRAPHIC 2027
4 GRAPHIC g379513note1.jpg GRAPHIC 1648
5 GRAPHIC g379513note2.jpg GRAPHIC 1415
6 GRAPHIC g379513note3.jpg GRAPHIC 1663
  Complete submission text file 0001193125-17-140858.txt   52584
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-34186 | Film No.: 17786182
SIC: 2834 Pharmaceutical Preparations